[Market Realist] Intercept Pharmaceuticals Inc (NASDAQ:ICPT)(TREND ANALYSIS) IBB’s biotechnology subgroup outperforms
The iShares Nasdaq Biotechnology ETF’s (IBB) biotechnology subgroup outperformed the biotechnology subgroups of the Health Care Select Sector SPDR ETF (XLV) and the SPDR S&P Biotechnology ETF (XBI). They had returns of 2.7%, 2.6%, and 2.2%, respectively, on October 7, 2015.
Intercept Pharmaceuticals (ICPT) is the other stock that rose 8% for the day. The stock closed at $179.51. It was trading above the 20-day moving average, but below the 50-day and 100-day moving averages. The 14-day RSI stood at 38. This indicates that the stock isn’t oversold or overbought. The short interest-to-total equity ratio stood at ~16%. The short interest indicates the short position—this means that the shares are sold but not bought back. ICPT has a weight of 1% in XBI and 0.7% in IBB.
Stock Performance: Click here for a free comprehensive Trend Analysis Report
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) stock is currently trading 46.76% below its 52-week-high, 30.46% above its 52-week-low. The 1-year stock price history is in the range of $128.5 – $314.88. Intercept Pharmaceuticals Inc (ICPT) has a price to book ratio of 4.98. ICPT stock price has underperformed the Nasdaq by 2.3%. The Biotechnology company is currently valued at $4.06 billion and its share price closed the last trading session at $167.64. The stock has a 50-day moving average of $178.34 and a 200-day moving average of $232.03.
Intercept Pharmaceuticals Inc (ICPT) current short interest stands at 2.57 million shares. It has decreased by 4% from the same period of last month. Around 16% of the company’s shares, which are float, are short sold. With a 10-days average volume of 0.38 million shares, the number of days required to cover the short positions stand at 6.8 days.
The company is expected to announce this quarter earnings on November 05, at consensus estimate of $-2.6. Intercept Pharmaceuticals Inc (ICPT) reported last quarter earnings on August 05. The Biotechnology company announced earnings per share of $-1.99 against a consensus Street estimate of $-1.94, missing estimate by $0.05. This corresponds to a decrease of $3.45 compared to the same quarter of the previous fiscal year.
Is this a Buying Opportunity? Click here for a free Trend Analysis Report
There are currently sixteen analysts that cover Intercept Pharmaceuticals Inc stock. Of those sixteen, twelve have a Buy rating, three have a Hold rating and one has a Sell rating. On a consensus basis this yields to an Overweight rating. The consensus target price stands at $391.94.
A recent analyst activity consisted of Morgan Stanley who initiated their coverage on the stock with Underweight rating on August 13. Morgan Stanley fixed their price target at $165. This corresponds to a 1.57% downside from the last closing price. On the date of report, the stock closed at $213.99.
Barclays initiated their coverage on the stock with Overweight rating on May 21, and fixed their price target at $425. This corresponds to a 153.52% upside from the last closing price. On the date of report, the stock closed at $265.69.
Another research firm was Bank of America who downgraded their Buy rating to Neutral on May 19. On the date of report, the stock closed at $263.5.
Intercept Pharmaceuticals, Inc. manufactures and markets biopharmaceutical products. The Company focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. Intercept Pharmaceuticals serves customers throughout the United States.